

Leading in sustainability

Conference call and webcast for analysts, institutional investors and rating agencies

9 September 2020
Session is being recorded



Forward-looking statements disclaimer

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective intellectual property (IP) protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.



Speakers



Leif Johansson

Non-Executive Chairman of the Board



Katarina Ageborg

Executive Vice-President,
Sustainability and Chief Compliance
Officer; President AstraZeneca AB,
Sweden



Agenda

-  Commitment
-  Governance
-  Leadership
-  Closing and Q&A



Commitment to sustainability



Why is sustainability so important now?



The World Health Organization estimates that **air pollution kills 7 million people each year.**



In some high-income countries, cancer survival rates for children can be 80%. **In many low-income countries, it's 20%.**



Plastic waste is found in the guts of more than **90% of the world's sea birds.**



The World Economic Forum predicts that **it will take more than two centuries to achieve pay equality** in the workplace.



AstraZeneca's commitment to sustainability

We use our capabilities to make the most meaningful impact where society needs it — **health**.

We believe there is a strong connection between the health of our patients, our business, our workforce, our communities and the planet, and each of these impact one another.



Governance of sustainability



Governance

Board of Directors

- Non-Executive Director Geneviève Berger oversees sustainability matters on behalf of the Board

Senior Executive Team (SET)

- Accountable for specific sustainability initiatives and review of the sustainability scorecard each quarter.
- SET Sustainability rep:
Katarina Ageborg, EVP, Sustainability and Chief Compliance Officer, President AstraZeneca AB, Sweden

Sustainability Advisory Board

- SET members
- External sustainability experts



We have well defined priorities



Access to Healthcare

Health is at the heart of our business

Our ambitions for 2025

Address the global burden of NCDs through a holistic approach – from prevention to pipeline to treatment

Our focus areas

- Investments in health systems
- Affordability
- Responsible R&D
- Environment's impact on health
- Disease prevention and treatment



Environmental Protection

The health of the planet impacts all life

Manage our environmental impact across all our activities and our products

- Product environmental stewardship
- Greenhouse gas reduction
- Pharmaceutical in the environment
- Water stewardship
- Waste management



Ethics and Transparency

Healthy societies promote equality and prosperity for all

Create positive societal impact and promote ethical behaviour in all markets across our value chain

- Ethical business culture
- Inclusion and diversity
- Talent and workforce evolution
- Workforce wellbeing and safety
- Responsible supply chain
- Human rights



Leadership in sustainability



We can all make an impact



At AstraZeneca, we all work to make the world a better place. We push the boundaries of science to deliver life-changing medicines to the people who need them.

Our focus on sustainability is integral to our efforts, and we continue to make advancements across our three priority areas – increasing access to healthcare, protecting the environment and demonstrating our commitment to ethics and transparency.”

Pascal Soriot
Executive Director and CEO



Our United Nations SDG impact




Access to Healthcare

Health is at the heart of our business



SDG 3 –
Good health and wellbeing



SDG 8 –
Decent work and economic growth



SDG 17 –
Partnership for the goals



Environmental Protection

The health of the planet impacts all life



SDG 12 –
Responsible consumption and production



SDG 13 –
Climate action



SDG 17 –
Partnership for the goals




Ethics and Transparency

Healthy societies promote equality and prosperity for all



SDG 5 –
Gender equality



SDG 8 –
Decent work and economic growth



SDG 17 –
Partnership for the goals




Access to healthcare





Access to Healthcare



Access to healthcare – impact



81,000+

healthcare workers
trained (cumulative)



19.8m+

reached
through access
programmes
(cumulative)



9.7m+

reached through Patient
Assistance Programmes
(cumulative)



UNGC

Patron sponsor of
Business Ambition for
Climate and Health




Environmental protection





Environmental protection



Environmental protection – impact




Zero
carbon
emission
commitment
by 2025 (sites
and fleet)



11%
reduction
in Scope 1
emissions



11%
increase in our
waste



62%
of our
electricity is
renewable



18%
reduction in
our water use



97%
of API
discharges from
direct suppliers
demonstrated
as safe




Ethics and transparency





Ethics and transparency



Ethics and transparency – impact



45.4%

women in
management
roles



63.3

instances of non-
compliance with the
Code of Ethics per
1,000 employees



86%

feel that
AstraZeneca is
a Great Place
to Work



96

countries disclosing
data points on
Sustainability
Transparency Map



89

manufacturing
partners were
evaluated



Q&A panel



Leif Johansson

Non-Executive Chairman of the Board



Katarina Ageborg

Executive Vice-President,
Sustainability and Chief Compliance
Officer; President AstraZeneca AB,
Sweden



Ashling Mulvaney

Head of Access to Healthcare



Jason Snape

Head of Environmental Protection



Heather Stewart

Head of Ethics and Transparency



Questions & Answers



Use of AstraZeneca conference call, webcast and presentation slides

The AstraZeneca webcast, conference call and presentation slides (together the 'AstraZeneca Materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca Materials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine the AstraZeneca Materials with any other material. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com

